A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Kidney International

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Urology

Show all topics

DOI

10.1016/j.kint.2021.03.033

License

CC-BY

Other Formats

PDF